These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32574395)

  • 21. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease.
    Vinereanu D; Wang A; Mulder H; Lopes RD; Jansky P; Lewis BS; Gersh BJ; Avezum A; Hanna M; Held C; Wallentin L; Granger CB; Alexander JH
    Heart; 2018 Aug; 104(15):1292-1299. PubMed ID: 29352007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis.
    Banerjee A; Allan V; Denaxas S; Shah A; Kotecha D; Lambiase PD; Joseph J; Lund LH; Hemingway H
    Europace; 2019 Dec; 21(12):1776-1784. PubMed ID: 31408153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease.
    Dawwas GK; Barnes GD
    Curr Cardiol Rep; 2022 Jun; 24(6):731-738. PubMed ID: 35460473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to define valvular atrial fibrillation?
    Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
    Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study.
    Ording AG; Horváth-Puhó E; Adelborg K; Pedersen L; Prandoni P; Sørensen HT
    Cancer Med; 2017 Jun; 6(6):1165-1172. PubMed ID: 28544489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antithrombotic treatment of patients with valvular atrial fibrillation].
    Bovin A; Christensen TD; Grove EL
    Ugeskr Laeger; 2017 Jul; 179(29):. PubMed ID: 28789760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.
    Lip GY; Laroche C; Popescu MI; Rasmussen LH; Vitali-Serdoz L; Dan GA; Kalarus Z; Crijns HJ; Oliveira MM; Tavazzi L; Maggioni AP; Boriani G
    Europace; 2015 Dec; 17(12):1777-86. PubMed ID: 26321406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta-analysis.
    Romero J; Cerrud-Rodriguez RC; Diaz JC; Rodriguez D; Arshad S; Alviz I; Cerna L; Rios S; Monhanty S; Natale A; Garcia MJ; Di Biase L
    J Cardiovasc Electrophysiol; 2019 Aug; 30(8):1250-1257. PubMed ID: 31257677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma beta-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation.
    Yamauchi K; Furui H; Taniguchi N; Sotobata I
    Jpn Heart J; 1986 Jul; 27(4):481-7. PubMed ID: 2946878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
    Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thromboembolic risks associated with paroxysmal and persistent atrial fibrillation in Asian patients: a report from the Chinese atrial fibrillation registry.
    Wang Y; Ma CS; Du X; He L; Li J; Wang GH; Wen D; Dong JZ; Pan JH; Lip GYH
    BMC Cardiovasc Disord; 2019 Nov; 19(1):283. PubMed ID: 31810439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease.
    Strange JE; Sindet-Pedersen C; Staerk L; Grove EL; Gerds TA; Torp-Pedersen C; Gislason GH; Olesen JB
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f93-f100. PubMed ID: 32065652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
    Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
    Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin.
    Luengsupabul S; Methavigul K; Methavigul R
    J Arrhythm; 2020 Jun; 36(3):425-429. PubMed ID: 32528567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.
    Olesen JB; Lip GY; Lindhardsen J; Lane DA; Ahlehoff O; Hansen ML; Raunsø J; Tolstrup JS; Hansen PR; Gislason GH; Torp-Pedersen C
    Thromb Haemost; 2011 Oct; 106(4):739-49. PubMed ID: 21789337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis.
    de Souza Lima Bitar Y; Neto MG; Filho JAL; Pereira LV; Travassos KSO; Akrami KM; Roever L; Duraes AR
    Drugs R D; 2019 Jun; 19(2):117-126. PubMed ID: 31055767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Young Male Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study.
    Chan YH; Wu LS; Chang SH; Lee HF; Liu JR; See LC; Yeh YH; Kuo CT
    PLoS One; 2016; 11(3):e0151485. PubMed ID: 26986069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry].
    Renda G; Patti G; Sangiuolo R; Attena E; Malpezzi MG; De Caterina R;
    G Ital Cardiol (Rome); 2016 Nov; 17(11):922-931. PubMed ID: 27996998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics and Prognosis of Patients With Nonvalvular Atrial Fibrillation and Significant Valvular Heart Disease Referred for Electrical Cardioversion.
    Vo NM; Leung M; van Rosendael PJ; Goedemans L; van Wijngaarden SE; Prihadi EA; van der Bijl P; Ajmone Marsan N; Delgado V; Bax JJ
    Am J Cardiol; 2020 Aug; 128():84-91. PubMed ID: 32650929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry.
    Contreras JP; Hong KN; Castillo J; Marzec LN; Hsu JC; Cannon CP; Yang S; Maddox TM
    Clin Cardiol; 2019 Mar; 42(3):339-345. PubMed ID: 30582177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.